Class Action Lawsuit Filed Against Zoetis Inc. for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm has alerted investors about a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for participation set for July 27, 2026.
- False Statements Allegation: The complaint alleges that Zoetis made false and misleading statements during the class period, resulting in investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Market Share Decline: Zoetis's Trio product has lost market share to competitors, while its dermatology products Apoquel and Cytopoint have also been adversely affected by the introduction of new competing treatments, intensifying the company's market challenges.
- Investor Losses: As the market became aware of Zoetis's actual situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 72.450
Low
130.00
Averages
154.20
High
200.00
Current: 72.450
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Lowers 2026 Revenue Outlook Amid Competitive Pressures
- Intensified Competition: Zoetis CEO Kristin Peck highlighted during the May Q1 earnings call that competition has intensified across key pet care categories, particularly in dermatology and parasiticides, leading to slowed market growth and negatively impacting the company's performance.
- Revenue Outlook Cut: The company lowered its 2026 revenue outlook to a range of $9.68 billion to $9.96 billion, down from the previous forecast of $9.83 billion to $10.03 billion, while also adjusting its EPS guidance to $6.85 to $7.00, indicating significant market pressures.
- Price Target Reduction: Barclays significantly reduced Zoetis' price target from $136 to $85, implying only an 18% upside potential based on the stock's last closing price, reflecting a pessimistic sentiment regarding the company's future performance.
- Investor Sentiment Shift: Despite Barclays' negative commentary, data from Koyfin shows that 11 out of 20 analysts still rate the stock as a 'Buy' or higher, indicating a divergence in market sentiment towards Zoetis amidst its recent challenges.
See More
Zoetis Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Zoetis, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by July 27, 2026, indicating significant legal risks that could impact the company's reputation.
- Disappointing Earnings: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year earnings guidance to between $6.85 and $7.00 per share from a previous range of $7.00 to $7.10, reflecting operational challenges and softening market demand.
- Stock Price Plunge: Following the earnings report, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31, highlighting investor concerns regarding the company's future profitability and potentially leading to further declines in market confidence.
- Changing Market Dynamics: CEO Kristin Peck noted increased price sensitivity among pet owners, resulting in fewer veterinary visits and weaker demand, indicating that the company faces escalating challenges in the current economic environment, which may affect its long-term growth prospects.
See More
Class Action Lawsuit Filed Against Zoetis Inc. for Securities Violations
- Class Action Reminder: The Schall Law Firm has alerted investors about a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for participation set for July 27, 2026.
- False Statements Allegation: The complaint alleges that Zoetis made false and misleading statements during the class period, resulting in investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Market Share Decline: Zoetis's Trio product has lost market share to competitors, while its dermatology products Apoquel and Cytopoint have also been adversely affected by the introduction of new competing treatments, intensifying the company's market challenges.
- Investor Losses: As the market became aware of Zoetis's actual situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
See More
Zoetis Faces Class Action Lawsuit Over Securities Fraud
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a class action lawsuit against Zoetis Inc. on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, highlighting serious concerns over the company's financial transparency.
- Market Reaction: Following the release of its first-quarter 2026 financial results, Zoetis's stock plummeted by 21.5% due to significant declines in its Companion Animal business, indicating a pessimistic outlook from the market regarding the company's future prospects.
- Allegation Details: The lawsuit alleges that Zoetis failed to disclose critical information about the market performance and safety issues of products like Librela and Simparica Trio throughout the class period, preventing investors from understanding the true operational status of the company.
- Investor Action: Affected investors must apply for lead plaintiff status by July 27, 2026, to represent other investors in the lawsuit, reflecting a strong demand for improved corporate governance and transparency from the company.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements regarding its flagship products' market share growth and accelerating sales, failing to disclose the weakening veterinarian prescription growth and market share losses, resulting in investor damages.
- Market Reaction: Following FDA safety warnings, investor confidence in Zoetis's market performance has been shaken, particularly as the prescription growth for its canine pain treatment Librela sharply declined, impacting the company's overall performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Reminder of Zoetis Securities Fraud Class Action
- Class Action Reminder: Bernstein Liebhard LLP reminds investors of Zoetis Inc. that the deadline to join the securities fraud class action lawsuit is July 27, 2026, requiring prompt submission of necessary documents to participate in the litigation.
- Lawsuit Context: The lawsuit involves investors who purchased or acquired Zoetis securities between January 14, 2025, and May 6, 2026, alleging violations of the Securities Exchange Act of 1934 due to materially false and misleading statements made by the company and its senior officers.
- Investor Losses: These misrepresentations led to artificially inflated trading prices of Zoetis securities during the class period, resulting in significant losses for investors when the truth was revealed, highlighting serious concerns regarding the company's financial stability and growth prospects.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which facilitates participation in the lawsuit and encourages more affected investors to take action.
See More
Zoetis Lowers 2026 Revenue Outlook Amid Competitive Pressures
- Intensified Competition: Zoetis CEO Kristin Peck highlighted during the May Q1 earnings call that competition has intensified across key pet care categories, particularly in dermatology and parasiticides, leading to slowed market growth and negatively impacting the company's performance.
- Revenue Outlook Cut: The company lowered its 2026 revenue outlook to a range of $9.68 billion to $9.96 billion, down from the previous forecast of $9.83 billion to $10.03 billion, while also adjusting its EPS guidance to $6.85 to $7.00, indicating significant market pressures.
- Price Target Reduction: Barclays significantly reduced Zoetis' price target from $136 to $85, implying only an 18% upside potential based on the stock's last closing price, reflecting a pessimistic sentiment regarding the company's future performance.
- Investor Sentiment Shift: Despite Barclays' negative commentary, data from Koyfin shows that 11 out of 20 analysts still rate the stock as a 'Buy' or higher, indicating a divergence in market sentiment towards Zoetis amidst its recent challenges.
See More
Zoetis Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Zoetis, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by July 27, 2026, indicating significant legal risks that could impact the company's reputation.
- Disappointing Earnings: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year earnings guidance to between $6.85 and $7.00 per share from a previous range of $7.00 to $7.10, reflecting operational challenges and softening market demand.
- Stock Price Plunge: Following the earnings report, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31, highlighting investor concerns regarding the company's future profitability and potentially leading to further declines in market confidence.
- Changing Market Dynamics: CEO Kristin Peck noted increased price sensitivity among pet owners, resulting in fewer veterinary visits and weaker demand, indicating that the company faces escalating challenges in the current economic environment, which may affect its long-term growth prospects.
See More
Class Action Lawsuit Filed Against Zoetis Inc. for Securities Violations
- Class Action Reminder: The Schall Law Firm has alerted investors about a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for participation set for July 27, 2026.
- False Statements Allegation: The complaint alleges that Zoetis made false and misleading statements during the class period, resulting in investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Market Share Decline: Zoetis's Trio product has lost market share to competitors, while its dermatology products Apoquel and Cytopoint have also been adversely affected by the introduction of new competing treatments, intensifying the company's market challenges.
- Investor Losses: As the market became aware of Zoetis's actual situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
See More
Zoetis Faces Class Action Lawsuit Over Securities Fraud
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a class action lawsuit against Zoetis Inc. on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, highlighting serious concerns over the company's financial transparency.
- Market Reaction: Following the release of its first-quarter 2026 financial results, Zoetis's stock plummeted by 21.5% due to significant declines in its Companion Animal business, indicating a pessimistic outlook from the market regarding the company's future prospects.
- Allegation Details: The lawsuit alleges that Zoetis failed to disclose critical information about the market performance and safety issues of products like Librela and Simparica Trio throughout the class period, preventing investors from understanding the true operational status of the company.
- Investor Action: Affected investors must apply for lead plaintiff status by July 27, 2026, to represent other investors in the lawsuit, reflecting a strong demand for improved corporate governance and transparency from the company.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements regarding its flagship products' market share growth and accelerating sales, failing to disclose the weakening veterinarian prescription growth and market share losses, resulting in investor damages.
- Market Reaction: Following FDA safety warnings, investor confidence in Zoetis's market performance has been shaken, particularly as the prescription growth for its canine pain treatment Librela sharply declined, impacting the company's overall performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Reminder of Zoetis Securities Fraud Class Action
- Class Action Reminder: Bernstein Liebhard LLP reminds investors of Zoetis Inc. that the deadline to join the securities fraud class action lawsuit is July 27, 2026, requiring prompt submission of necessary documents to participate in the litigation.
- Lawsuit Context: The lawsuit involves investors who purchased or acquired Zoetis securities between January 14, 2025, and May 6, 2026, alleging violations of the Securities Exchange Act of 1934 due to materially false and misleading statements made by the company and its senior officers.
- Investor Losses: These misrepresentations led to artificially inflated trading prices of Zoetis securities during the class period, resulting in significant losses for investors when the truth was revealed, highlighting serious concerns regarding the company's financial stability and growth prospects.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which facilitates participation in the lawsuit and encourages more affected investors to take action.
See More
